Resources | NITAG RESOURCE CENTER

2024 ∙ NACI

Economic Evidence Supplementary Appendix to the Recommendations for Public Health Programs on the Use of Pneumococcal Vaccines in Children, Including the Use of 15-Valent and 20-Valent Conjugate Vaccines

2024 ∙ NACI

Recommendations for public health programs on the use of pneumococcal vaccines in children, including the use of 15-valent and 20-valent conjugate vaccines

2024 ∙ JCVI

JCVI statement on COVID-19 vaccination in spring 2024 and considerations on future COVID-19 vaccination

2024

Considerations to inform country COVID-19 vaccination decision-making

2024 ∙ ATAGI

ATAGI statement on Nirsevimab for the prevention of severe disease due to respiratory syncytial virus (RSV) in infants

2024 ∙ NACI

Guidance on an additional dose of COVID-19 vaccines in the spring for individuals at high risk of severe illness due to COVID-19

2023 ∙ Eiden, Amanda L. Barratt, Jane Nyaku, Mawuli K.

A review of factors influencing vaccination policies and programs for older adults globally

2023 ∙ Xu, K. Wang, Z. Qin, M. Gao, Y. Luo, N. Xie, W. Zou, Y. Wang, J. Ma, X.

A systematic review and meta-analysis of the effectiveness and safety of COVID-19 vaccination in older adults

2023 ∙ Tavabe, Nilay Rezaei Kheiri, Soleiman Dehghani, Mohsen Mohammadian-Hafshejani, Abdollah

A Systematic Review and Meta-Analysis of the Relationship between Receiving the Flu Vaccine with Acute Cerebrovascular Accident and Its Hospitalization in the Elderly

2023 ∙ Chen, S. Wei, W. Huang, F. Wang, J. Li, X. Gen, Z. Gao, F. Dong, T. Wei, P. Yang, X. Miao, F.

A systematic review and meta-analysis of the seroconversion rates and adverse effects of COVID-19 mRNA vaccine and COVID-19 viral vector vaccine in kidney transplant recipient patients